LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Recommendation of “Moderate Buy” from Analysts

LENZ Therapeutics, Inc. (NASDAQ:LENZ) has been assigned an average rating of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $28.80.

Several research firms have recently weighed in on LENZ. HC Wainwright reissued a “buy” rating on shares of LENZ Therapeutics in a research note on Tuesday, July 7th. Piper Sandler cut their target price on LENZ Therapeutics from $12.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 12th. Zacks Research raised LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Weiss Ratings lowered LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Finally, Citigroup restated a “buy” rating on shares of LENZ Therapeutics in a report on Wednesday, August 12th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP purchased a new position in LENZ Therapeutics during the 3rd quarter valued at about $27,000. State of Wyoming acquired a new position in LENZ Therapeutics in the fourth quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd bought a new position in LENZ Therapeutics during the fourth quarter valued at approximately $32,000. Osaic Holdings Inc. lifted its stake in LENZ Therapeutics by 2,146.2% in the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after acquiring an additional 1,116 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in LENZ Therapeutics by 51.4% in the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after acquiring an additional 477 shares during the last quarter. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Trading Down 1.8%

LENZ stock traded down $0.09 on Monday, hitting $4.59. 81,025 shares of the company’s stock traded hands, compared to its average volume of 938,973. The stock has a market cap of $144.37 million, a price-to-earnings ratio of -1.12 and a beta of 0.65. LENZ Therapeutics has a 1-year low of $4.53 and a 1-year high of $50.40. The stock has a fifty day moving average of $5.45 and a 200-day moving average of $8.48.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to analyst estimates of $2.38 million. LENZ Therapeutics had a negative net margin of 586.74% and a negative return on equity of 53.39%. On average, equities research analysts anticipate that LENZ Therapeutics will post -4.18 earnings per share for the current fiscal year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.